Isotyping paranodal antibodies in inflammatory neuropathies
One step closer to precision care
Citation Manager Formats
Make Comment
See Comments

Article Information
- First Published July 24, 2020.
Author Disclosures
- Cinta Lleixà, BSc and
- Luis Querol, MD, PhD
- Cinta Lleixà, BSc and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Luis Querol, MD, PhD
Commercial entity: Sanofi-Genzyme, CSL Bering, Grifols, Novartis, UCB Pharma, Johnson and Johnson, Alexion, Annexon
NONE
Commercial: CSL Behring, Novartis, Roche and Biogen, travel grant
Editorial Board Member of the European Journal of Neurology
NONE
NONE
NONE
NONE
Commercial: CSL Behring, Roche, Sanofi, Grifols, Merck, Novartis
NONE
NONE
Grifols
(1) Fondo de Investigaciones Sanitarias, PI19/01407 (2) SLT006/17/00131 of the Pla estratègic de Recerca i Innovació en Salut (PERIS), Departament de Salut, Generalitat de Catalunya (3) ACCI 2019-30 CIBERER
NONE
GBS-CIDP Foundation International
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neuromuscular Diseases Unit (C.L., L.Q.), Neurology Department, Hospital de la Santa Creu I Sant Pau, Barcelona; and Centro para la Investigación Biomédica en Red en Enfermedades Raras (C.L., L.Q.), CIBERER, Madrid, Spain.
- Correspondence
Dr. Querol lquerol{at}santpau.cat
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDPClinical relevance of IgG isotypeAndrea Cortese, Raffaella Lombardi, Chiara Briani et al.Neurology: Neuroimmunology & Neuroinflammation, November 21, 2019 -
Article
Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathyLuise Appeltshauser, Anna-Michelle Brunder, Annika Heinius et al.Neurology: Neuroimmunology & Neuroinflammation, July 24, 2020 -
Article
Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIgLuis Querol, Gisela Nogales-Gadea, Ricardo Rojas-Garcia et al.Neurology, February 12, 2014 -
Article
Anti–pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathyHelena Stengel, Atay Vural, Anna-Michelle Brunder et al.Neurology: Neuroimmunology & Neuroinflammation, August 16, 2019